Nalaganje...
Nivolumab Use for First-Line Management of Hepatocellular Carcinoma: Results of a Real-World Cohort of Patients
BACKGROUND: Patients with advanced hepatocellular carcinoma (HCC) have a poor prognosis. First-line multikinase inhibitors like sorafenib and lenvatinib are poorly tolerated and have low response rates. Several clinical trials have shown tolerability and efficacy of immunotherapy in this setting. Th...
Shranjeno v:
| izdano v: | Fed Pract |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontline Medical Communications Inc.
2021
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7953859/ https://ncbi.nlm.nih.gov/pubmed/33716486 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12788/fp.0061 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|